These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 14965331)

  • 1. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
    Murata M
    Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zonisamide: a new drug for Parkinson's disease.
    Murata M
    Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The discovery of an antiparkinsonian drug, zonisamide].
    Murata M
    Rinsho Shinkeigaku; 2010 Feb; 50(2):67-73. PubMed ID: 20196486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Discovery of an antiparkinsonian drug: zonisamide].
    Murata M
    Rinsho Shinkeigaku; 2010 Nov; 50(11):780-2. PubMed ID: 21921440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
    Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
    J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of Parkinson's disease--up to date].
    Murata M
    Rinsho Shinkeigaku; 2008 Nov; 48(11):986-8. PubMed ID: 19198140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
    Janszky J
    Ideggyogy Sz; 2009 Nov; 62(11-12):383-9. PubMed ID: 20025128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
    Tsujii S; Ishisaka M; Shimazawa M; Hashizume T; Hara H
    Eur J Pharmacol; 2015 Jan; 746():301-7. PubMed ID: 25261037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.
    Ikeda K; Yanagihashi M; Miura K; Ishikawa Y; Hirayama T; Takazawa T; Kano O; Kawabe K; Mizumura N; Iwasaki Y
    J Neurol Sci; 2018 Aug; 391():5-9. PubMed ID: 30103971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Miyoshi K; Ogawa N; Murata M
    Neurosci Res; 2008 Jan; 60(1):106-13. PubMed ID: 18022268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of zonisamide target astrocyte.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Kimoto N; Kikkawa Y; Takeshima M; Miyoshi K; Murata M
    Ann Neurol; 2010 Feb; 67(2):239-49. PubMed ID: 20225289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
    Yamamura S; Ohoyama K; Nagase H; Okada M
    Neuropharmacology; 2009 Sep; 57(3):322-31. PubMed ID: 19482038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
    PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
    Gluck MR; Santana LA; Granson H; Yahr MD
    J Neural Transm (Vienna); 2004 Jun; 111(6):713-24. PubMed ID: 15168218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zonisamide: aspects in neuroprotection.
    Rösler TW; Arias-Carrión O; Höglinger GU
    Exp Neurol; 2010 Aug; 224(2):336-9. PubMed ID: 20450911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I; Fukasaka J; Kochi K; Shimazu R;
    Mov Disord; 2015 Sep; 30(10):1343-50. PubMed ID: 26094993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.